menu

Quintiles Library

Show Filters
White Paper
As our knowledge of biomarkers increases, new studies are uncovering promising news on treating breast cancer. This emerging technology is already helping to predict which cancers – and which patients – will respond best to specific drugs. Molecular biologist and oncology expert Dr. Jason Hill summarizes six important studies presented at the 2009 San Antonio Breast...
Explore here
White Paper
The biopharmaceutical industry is at an important crossroads in medical innovation. Drug developers must seize opportunity to find a more efficient, scalable way to recruit patients for clinical trials, or face costly delays in bringing new medicines to market. Amid increasing costs, declining productivity, decreasing pipelines and a host of other challenges plaguing the...
Explore here
Press Release
RALEIGH, NC – February 17, 2010 – Quintiles today launched innovative, web-based technology to enable world-class marketing for clinical trial enrollment at an individual site-level.  Named Quintiles Trial Enrollment Accelerator (QTEA), this new solution will speed patient recruitment by helping customers better manage the quality, consistency and effectiveness of...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – February 16, 2010 – Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to...
Read More
Media Coverage
Quintiles' approach to increased partnering with customers was profiled in a full-length, national article from the Associated Press (AP) which saw publication in many leading news outlets. The AP story was entitled, "Private Drug Tester Expands Stake In Big Pharma" in most usages.  Below are links to a sampling of these stories: New York Times - DealBook - Quintiles...
Read more
Media Coverage
Journal Article: Cheryl Key, Barry Mulchrone and Karen Wai describe an electronic database for tracking RMPs for drugs approved in the European Union and explain why it is crucial for sponsors submitting marketing applications to have a thorough knowledge of safety plans already required for similar products. (Published in the February 2010 issue of The Regulatory Affairs...
Read more
Case Study
As is often the case, the major challenge was in recruiting a sufficient number of patients. In this study, the challenge was exacerbated by an aggressive timeline, the need to include only IBS patients who were not experiencing constipation, and the existence of competing non-constipation IBS studies. Quintiles was able to anticipate recruiting challenges and was...
Read more
Case Study
During the eight weeks the study was halted, Quintiles worked to keep investigators motivated by carefully and thoroughly explaining the protocol changes and providing regular communications and updates. The result is that, even with the protocol amendment, Quintiles met the enrollment deadline in eight months rather than the targeted ten months — a full two months early....
Read more
Press Release
Quintiles, the world’s leading biopharmaceutical services company, has again been named to Training magazine’s “Training Top 125,” the publication’s annual report that ranks companies based on their employer-sponsored training and development programs. Quintiles rises to # 47 on the list after coming in at # 80 in 2009, the company’s first time in the rankings. Past...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. & TURNHOUT, BELGIUM – January 28, 2010 – Quintiles today announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will execute a comprehensive commercial sales effort for the product launch and provide additional services in...
Read More
Press Release
Research Triangle Park, NC, January 25, 2010 - Quintiles, the world’s leading biopharmaceutical services company, has launched a new positioning and brand identity, driven by the company’s growing ability to solve customers’ emerging clinical and commercial challenges. The New Health “The New Health is our description of the rapidly changing world of biopharma,” said...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – January 19, 2010 – Quintiles today announced that Paula Brown Stafford, Executive Vice President, Integrated Clinical Services, has been elected chair-elect of the Board of Directors of CDISC, a global organization that leads the development of standards to reduce complexity in biomedical research to speed new therapies to market and improve...
Read More
Press Release
Collaboration to enhance value, effectiveness and speed in drug development RESEARCH TRIANGLE PARK, N.C. and PITTSBURGH, PA - January 18, 2010 - Quintiles, the world’s leading biopharmaceutical services company, and invivodata, inc., an industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, today announced a collaboration...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – Jan. 11, 2010 – While half of corporate alliances fail, Quintiles and Solvay Pharmaceuticals succeeded by focusing on alliance strategy execution and achieving common goals, according to the Harvard Business Review article “Managing Alliances with the Balanced Scorecard” available for download at www.quintiles.com. The article in Harvard...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – December 22, 2009 – Quintiles today announced it has developed a community of more than 2 million clinically profiled patients who have opted in to volunteer or provide insights and guidance to advance clinical research through its proprietary Web site iGuard.org.iGuard, launched by Quintiles two years ago, is a personalized medication...
Read More
Press Release
Research Triangle Park, NC, – December 14, 2009 – Quintiles has been named CRO of the Year by the prestigious SCRIP Awards. The panel of judges highlighted Quintiles’ breadth of services and its outstanding relationships with clients. The UK-based SCRIP Awards acknowledge excellence in the biopharmaceutical industry and are judged by an illustrious panel of life sciences...
Read More
Presentation
In the wake of the December 2008 FDA Guidance for Industry on cardiovascular safety assessments, Dr. Rick Turner began to consider how cardiac and cardiovascular safety could be integrated in assessing products in development. In this presentation from the October 2009 DIA webinar on cardiac safety, he outlines his model to prospectively rule out unacceptable...
Explore more
White Paper
The new emphasis on assessing cardiovascular risk for diabetes patients is the latest turn in the FDA’s focus on diabetes drug development. To help you identify the full implications of the 2008 FDA Guidance on antidiabetic therapies on your development plans, two of our top experts in diabetes and cardiac safety have teamed up to take a closer look at the FDA’s...
Explore here
Presentation
Why are modeling and simulation important in cardiac safety? How are they different? In this presentation from the October 2009 DIA webinar on cardiac safety, Dr. Giri Tirucherai makes a compelling case for using both modeling and simulation in early product development to leverage data from early clinical studies to design optimal TQT studies. Learn how this approach...
Explore more
Presentation
Poster ISPOR EU - Health Related Quality of Life, EDSS and Timed 25-foot Walk in a Multiple Sclerosis Population of a Real-World Observational Outcomes Study: Baseline Data from ROBUST  
Explore more